Chronic lymphocytic leukemia<unk>  is used for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in people who have been treated with alkylating agents and who have failed fludarabine therapy. It is an unconjugated antibody, thought to work via the activation of antibody-dependent cell-mediated cytotoxicity (ADCC). Multiple sclerosis It is used for the relapsing remitting form of multiple sclerosis. A 2017 Cochrane meta-analysis of studies comparing<unk>  to interferon beta 1a concluded that annual cycles of<unk>  probably reduces the proportion of people that experience relapse and may reduce the proportion of people who experience disability worsening and new T2 lesions on MRI, with adverse events found to be similarly high for both treatments. However the low-to-moderate levels of evidence in the included, existing studies were noted and the need for larger high-quality randomised, double‐blind, controlled trials comparing mono or combination therapy with<unk>  was highlighted. It is generally only recommended in people do not respond sufficiently to at least two other MS medications.
Alemtuzumab
Ruxolitinib
Rituximab
Lenalidomide
Imatinib
Ibrutinib
Bosutinib
Ponatinib